Arcutis Biotherapeutics (ARQT) said Tuesday that the US Food and Drug Administration has accepted its supplemental new drug application for Zoryve foam 0.3% to treat adults and adolescents aged 12 and older with scalp and body psoriasis.
The FDA has set a Prescription Drug User Fee Act target action date of May 22, 2025, the commercial-stage company said.
The sNDA is backed by positive data from Arcutis' pivotal late-stage trial, a phase 2b study, as well as long-term efficacy and safety data generated from the Zoryve cream development program in plaque psoriasis, the company said.
Price: 9.67, Change: +0.04, Percent Change: +0.42
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。